- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07357597
Een open-label, single-arm studie naar profylaxe voor met datopotamab deruxtecan (Dato-DXd) geassocieerde stomatitis bij in aanmerking komende patiënten met gemetastaseerde of inoperabele lokaal recidiverende borstkanker of lokaal gevorderde of gemetastaseerde niet-kleincellig longkanker met epidermale groeifactorreceptormutatie. (TROPION-SWISH)
Een fase IV, open-label, single-arm studie naar profylaxe voor met datopotamab deruxtecan geassocieerde stomatitis bij in aanmerking komende patiënten met gemetastaseerde of inoperabele lokaal recidiverende borstkanker of lokaal gevorderde of gemetastaseerde epidermale groeifactorreceptor-gemuteerde niet-kleincellige longkanker (TROPION-SWISH)
This is a multicenter, open-label, single-arm study of prophylaxis for Dato-DXd-related stomatitis in eligible patients with metastatic or inoperable locally recurrent breast cancer or locally advanced or metastatic Epidermal Growth Factor Receptor-Mutated (EGFRm) non-small cell lung cancer
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
The purpose of this Phase IV study is to describe the incidence and severity of Dato-DXd treatment-emergent grade ≥ 2 stomatitis in participants receiving prophylactic dexamethasone mouthwash within the first 12 weeks of study treatment (ie, Dato-DXd dosing).
The study will enroll an estimated 100 participants across approximately 35 sites in the U.S. Enrollment of participants is planned to occur over approximately 18 months, with a minimum of 12 weeks of follow-up for each participant after the first Dato-DXd dose.
This study has one arm, and the study population will consist of 2 independent cohorts (approximately 50 participants in each cohort):
- Breast cohort (Cohort 1)
- Lung cohort (Cohort 2)
Participants will receive the study intervention, dexamethasone mouthwash, throughout the duration of their standard of care treatment with Dato-DXd.
Studietype
Inschrijving (Geschat)
Fase
- Fase 4
Contacten en locaties
Studiecontact
- Naam: AstraZeneca Clinical Study Information Center
- Telefoonnummer: 1-877-240-9479
- E-mail: information.center@astrazeneca.com
Studie Locaties
-
-
Arizona
-
Tucson, Arizona, Verenigde Staten, 85719
- Ingetrokken
- Research Site
-
-
Arkansas
-
Hot Springs, Arkansas, Verenigde Staten, 71913
- Werving
- Research Site
-
Little Rock, Arkansas, Verenigde Staten, 72205
- Werving
- Research Site
-
-
California
-
Duarte, California, Verenigde Staten, 91010
- Nog niet aan het werven
- Research Site
-
Glendale, California, Verenigde Staten, 91204
- Werving
- Research Site
-
Lakewood, California, Verenigde Staten, 90805
- Werving
- Research Site
-
Long Beach, California, Verenigde Staten, 90806
- Werving
- Research Site
-
Torrance, California, Verenigde Staten, 90505
- Nog niet aan het werven
- Research Site
-
-
District of Columbia
-
Washington D.C., District of Columbia, Verenigde Staten, 20037
- Ingetrokken
- Research Site
-
-
Florida
-
Coral Springs, Florida, Verenigde Staten, 33065
- Werving
- Research Site
-
Plantation, Florida, Verenigde Staten, 33322
- Werving
- Research Site
-
-
Georgia
-
Athens, Georgia, Verenigde Staten, 30607
- Werving
- Research Site
-
-
Idaho
-
Boise, Idaho, Verenigde Staten, 83706
- Ingetrokken
- Research Site
-
-
Illinois
-
Park Ridge, Illinois, Verenigde Staten, 60068
- Ingetrokken
- Research Site
-
-
Indiana
-
Fort Wayne, Indiana, Verenigde Staten, 46825
- Werving
- Research Site
-
-
Kentucky
-
Elizabethtown, Kentucky, Verenigde Staten, 42701
- Werving
- Research Site
-
Lexington, Kentucky, Verenigde Staten, 40503
- Werving
- Research Site
-
Lexington, Kentucky, Verenigde Staten, 40509
- Nog niet aan het werven
- Research Site
-
Louisville, Kentucky, Verenigde Staten, 40207
- Werving
- Research Site
-
-
Louisiana
-
New Orleans, Louisiana, Verenigde Staten, 70112
- Nog niet aan het werven
- Research Site
-
-
Maryland
-
Frederick, Maryland, Verenigde Staten, 21702
- Ingetrokken
- Research Site
-
Glenn Dale, Maryland, Verenigde Staten, 20769
- Nog niet aan het werven
- Research Site
-
-
Michigan
-
Detroit, Michigan, Verenigde Staten, 48202
- Nog niet aan het werven
- Research Site
-
Grayling, Michigan, Verenigde Staten, 49738
- Werving
- Research Site
-
-
Minnesota
-
Minneapolis, Minnesota, Verenigde Staten, 55426
- Werving
- Research Site
-
-
Missouri
-
Kansas City, Missouri, Verenigde Staten, 64111
- Werving
- Research Site
-
-
Nevada
-
Reno, Nevada, Verenigde Staten, 89502
- Ingetrokken
- Research Site
-
-
New Hampshire
-
Lebanon, New Hampshire, Verenigde Staten, 03756
- Ingetrokken
- Research Site
-
-
New York
-
East Syracuse, New York, Verenigde Staten, 13057
- Werving
- Research Site
-
Westbury, New York, Verenigde Staten, 11590
- Nog niet aan het werven
- Research Site
-
White Plains, New York, Verenigde Staten, 10601
- Ingetrokken
- Research Site
-
-
North Carolina
-
Greensboro, North Carolina, Verenigde Staten, 27403
- Nog niet aan het werven
- Research Site
-
Wilson, North Carolina, Verenigde Staten, 27893
- Werving
- Research Site
-
-
Ohio
-
Cleveland, Ohio, Verenigde Staten, 44106
- Nog niet aan het werven
- Research Site
-
-
Pennsylvania
-
Wynnewood, Pennsylvania, Verenigde Staten, 19096
- Werving
- Research Site
-
-
South Carolina
-
West Columbia, South Carolina, Verenigde Staten, 29169
- Nog niet aan het werven
- Research Site
-
-
Tennessee
-
Knoxville, Tennessee, Verenigde Staten, 37920
- Werving
- Research Site
-
-
Virginia
-
Fairfax, Virginia, Verenigde Staten, 22031
- Werving
- Research Site
-
-
West Virginia
-
Charleston, West Virginia, Verenigde Staten, 25304
- Ingetrokken
- Research Site
-
Morgantown, West Virginia, Verenigde Staten, 26506
- Werving
- Research Site
-
-
Wisconsin
-
Waukesha, Wisconsin, Verenigde Staten, 53188
- Werving
- Research Site
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
Patients are eligible to be included in the study only if all the following criteria apply:
Disease Characteristics
-
Patients with any of the following disease characteristics are eligible (specific population subject to FDA Dato-DXd label):
• Patients with unresectable or metastatic HR+/HER2- (IHC 0, IHC 1+, or IHC 2+/ISH-) breast cancer who have received prior ET and chemotherapy for unresectable or metastatic disease.
OR
• Adult patients with unresectable or metastatic TNBC who are not candidates for PD-1/PD-L1 inhibitor therapy. Participants will be enrolled upon FDA approval on use of Dato-DXd for this indication.
OR
• Patients with locally advanced or metastatic EGFRm NSCLC who have received prior EGFR-directed therapy and platinum-based chemotherapy.
Age
-
Patient must be ≥ 18 years, at the time of signing the informed consent.
Type of Patient and Disease Characteristics-
-
Has documentation that Dato-DXd will be prescribed for the labelled indication and has not received any dose of Dato-DXd prior to enrollment.
-
Is willing to comply with use of prophylactic dexamethasone mouthwash at the start of first infusion and throughout Dato-DXd administration.
-
ECOG performance status 0 or 1.
-
Has adequate bone marrow function (hemoglobin ≥ 9 g/dL; red blood cell/plasma transfusion is not allowed within 1 week prior to screening assessment).
-
All women of childbearing potential must have a negative serum pregnancy test result at screening.
Informed Consent
-
Capable of giving signed informed consent as described in the protocol which includes compliance with the requirements and restrictions listed in the ICF and the protocol.
Exclusion Criteria:
Patients are excluded from the study if any of the following criteria apply:
-
Has received Dato-DXd prior to enrollment.
Medical Conditions
-
As judged by the investigator, any evidence of cardiac, pulmonary, vascular, and other renal conditions which in the investigator's opinion makes it undesirable for the patient to participate in the study.
-
Has any-grade active and uncontrolled stomatitis or mouth ulcers at baseline (participants with prior medical history of stomatitis or mouth ulcers are eligible).
-
Use of steroid-containing mouthwash is contraindicated in, including but not limited to:
- Active oral infections (eg, viral, bacterial, or fungal), where the use of a steroid-containing mouthwash may impair local immune response and delay healing
- Known hypersensitivity or allergy to corticosteroids or any excipients contained in the mouthwash formulation
-
Uncontrolled infection requiring IV antibiotics, antivirals, or antifungals; suspected infections (eg, prodromal symptoms); or inability to rule out infections (participants with localized fungal infections of skin or nails are eligible).
-
Has clinically significant corneal disease.
-
Has a history of severe hypersensitivity reactions to either the drug or inactive ingredients of Dato-DXd (including, but not limited to, polysorbate 80).
-
Has a history of severe hypersensitivity reactions to other monoclonal antibodies.
-
Is pregnant, or breastfeeding, or planning to become pregnant.
Other Exclusions
-
Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).
-
Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions, and requirements.
-
Previous enrollment in the present study.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Preventie
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Dexamethasone 0.5 mg/5 mL Mouthwash
Participants will use dexamethasone 0.5 mg/5 mL alcohol-free mouthwash (10 mL, 4 times daily, swish for approximately 2 minutes, then spit out without swallowing). Participants will remain without food or drink for at least 30 minutes after use of dexamethasone |
Dexamethasone steroid-based oral solution, comprised of 0.5 milligrams per 5mL of alcohol-free dexamethasone. Commercially available Dato-DXd is prescribed and administered to participants according to standard of care
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Incidence and severity of Dato-DXd treatment-emergent grade ≥ 2 stomatitis in patients receiving prophylactic dexamethasone mouthwash within first 12 weeks of study treatment
Tijdsspanne: From date of first dose of study treatment until 12 weeks after date of first dose of study treatment
|
Incidence is defined as the proportion of participants who develop National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0 grade ≥ 2 stomatitis accompanied by either a Normalcy of Diet Subscale score ≤ 50 and/or a Numeric Rating Scale (NRS) oral-pain score of 7 on 2 consecutive days or 8, 9, or 10 on any one day. Severity will be based on the highest NCI-CTCAE v5.0 grade of stomatitis experienced by each participant. CTCAE displays Grades 1-5 with descriptions of severity for each adverse event (AE). Grade 1 for mild symptoms and Grade 5 for death related to AE. The Normalcy of Diet Subscale assesses the degree to which a patient can eat a normal diet and drink liquids. The scale is a ranking of 10 food categories, from easy-to-eat to difficult-to-eat. The Numeric Rating Scale is a scale for self-reporting of pain. Scores range from 0-10, with higher scores meaning the worst pain possible (0=no pain to 10=worst possible pain). |
From date of first dose of study treatment until 12 weeks after date of first dose of study treatment
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Incidence and severity of Dato-DXd treatment-emergent grade ≥ 2 stomatitis
Tijdsspanne: From date of first dose of study treatment until 6 and 9 weeks after date of first dose of study treatment
|
This will be determined using the composite stomatitis definition in the primary outcome. Will be repeated within 6 weeks and within 9 weeks of study treatment. |
From date of first dose of study treatment until 6 and 9 weeks after date of first dose of study treatment
|
|
Incidence and severity of treatment-emergent stomatitis overall, by maximum CTCAE grade, and CTCAE grade ≥ 2
Tijdsspanne: From date of first dose of study treatment until 6, 9 and 12 weeks after date of first dose of study treatment
|
This will be determined using stomatitis CTCAE grade only. Will be analysed at 6, 9 and 12 weeks. |
From date of first dose of study treatment until 6, 9 and 12 weeks after date of first dose of study treatment
|
|
Time to onset of grade ≥ 2 stomatitis
Tijdsspanne: From date of first dose until earliest of diagnosis of grade ≥2 stomatitis, Dato-DXD discontinuation and death, whichever occurs first, assessed up to approximately 21 months
|
The time (in days) from the date of the first dose of Dato-DXd to the date of first onset to a grade ≥ 2 stomatitis event. The measure of primary interest is median time to onset. |
From date of first dose until earliest of diagnosis of grade ≥2 stomatitis, Dato-DXD discontinuation and death, whichever occurs first, assessed up to approximately 21 months
|
|
Time to resolution of Dato-DXd-related grade ≥ 2 stomatitis
Tijdsspanne: From date of diagnosis of grade ≥2 stomatitis until the earliest date of event resolved or reduced in severity to grade 1, assessed up to approximately 21 months
|
Number of days from the date of onset of stomatitis grade ≥ 2 until the earliest date of event resolved or reduced in severity to grade 1. The measure of primary interest is median time to resolution. |
From date of diagnosis of grade ≥2 stomatitis until the earliest date of event resolved or reduced in severity to grade 1, assessed up to approximately 21 months
|
|
Proportion of participants with a dose modification for Dato-DXd due to stomatitis
Tijdsspanne: From date of first dose until earliest of Dato-DXD discontinuation and death, assessed up to approximately 21 months
|
Dose modification is defined as dose reduction, delay, or discontinuation due to stomatitis Treatment-Emergent Adverse Event (TEAE). |
From date of first dose until earliest of Dato-DXD discontinuation and death, assessed up to approximately 21 months
|
|
Participant adherence to dexamethasone mouthwash
Tijdsspanne: From date of first dose of study treatment until 12 weeks after date of first dose of study treatment
|
Adherence to dexamethasone mouthwash will be assessed by cohort using the Daily Activities Diary. The measure of primary interest is the median number of swished mouthwashes per day. |
From date of first dose of study treatment until 12 weeks after date of first dose of study treatment
|
|
Safety and tolerability of Dato-DXd in participants receiving prophylactic dexamethasone mouthwash
Tijdsspanne: From date of first dose of study intervention until 28 days after the last dose (Safety Follow-up), approximately 21 months
|
Safety and tolerability will be evaluated by cohort in terms of AEs (graded by NCI-CTCAE v5.0) and in terms of the following:
|
From date of first dose of study intervention until 28 days after the last dose (Safety Follow-up), approximately 21 months
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- D926UL00001
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD-tijdsbestek voor delen
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
IPD-toegangscriteria voor delen
When a request has been approved, AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
IPD delen Ondersteunend informatietype
- LEERPROTOCOOL
- SAP
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .